BioCentury | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

...took a €1.8 billion ($2 billion) impairment mainly related to sales of hemophilia drug Eloctate efmoroctocog alfa...
...SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) Elocta, Eloctate, antihemophilic factor (recombinant) fc fusion protein, efmoroctocog alfa (BIIB031, rfviiifc, Long-lasting rFACTOR VIII) Ingrezza...
BioCentury | Feb 8, 2018
Company News

Cardio/diabetes sales drag down Sanofi earnings

...of $780.7 million for the first nine months of 2017 for its hemophilia drugs Eloctate efmoroctocog alfa...
...York on Wednesday. Jaime De Leon Alprolix ALX-0081/ALX-0681 Anti-vWF Nanobody antihemophilic factor (recombinant) Fc fusion protein BIIB031 caplacizumab coagulation Factor IX (recombinant) Fc fusion protein dupilumab Dupixent efmoroctocog alfa eftrenonacog alfa Elocta Eloctate Long Acting rFactor lX REGN668 rFIXFc rFVIIIFc SAR231893 Ablynx...
BioCentury | Jan 27, 2018
Strategy

Growing up Genzyme

...is expected to be immediately accretive to EPS. Sanofi will gain marketed hemophilia therapies Eloctate efmoroctocog alfa...
...have historically been reluctant to switch from one treatment to another. Bioverativ’s Eloctate is an antihemophilic factor (recombinant) Fc fusion protein...
...and children with hemophilia A who have developed Factor VIII inhibitors. Nonetheless, Sanofi noted that Eloctate...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...on Jan. 19, before the deal was announced. The deal gives Sanofi marketed drugs Eloctate efmoroctocog alfa...
...disease (see BioCentury, Sept. 8, 2017 ). Swedish Orphan Biovitrum AB (SSE:SOBI) holds rights to Eloctate...
...three months. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Bioverativ Inc. (NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...off 3% on both Euronext and the NYSE. The deal gives Sanofi marketed drugs Eloctate efmoroctocog alfa...
...see BioCentury Extra, Sept. 6, 2017) . Swedish Orphan Biovitrum AB (SSE:SOBI) holds rights to Eloctate...
...to SEK135.70 on Monday. Sanofi and Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam...
BioCentury | Nov 16, 2017
Company News

FDA approves Genentech's Hemlibra for hemophilia A

...by Roche, initially developed emicizumab and Roche opted into development of the product in 2014. Chris Lieu Adynovate Eloctate emicizumab Bioverativ...
BioCentury | Apr 15, 2017
Product Development

Outside factors

...does not work for about 20% of patients. A three-patient open-label immune-tolerizing study of Eloctate antihemophilic factor (recombinant) Fc fusion protein...
...it eliminated inhibitors to Factor VIII. The open-label Phase III HIRE study, which is testing Eloctate...
...in hemophilia uptake. ” BioCentury (2012) Malec, L., et al. “Immune tolerance induction using Rfviiifc (Eloctate).”...
BioCentury | Feb 11, 2017
Strategy

Building Bioverativ

...which include two marketed long-acting clotting factor replacements and a portfolio of preclinical candidates. Eloctate antihemophilic factor (recombinant) Fc fusion protein...
...2016 sales of $888 million, and Bioverativ has guided for 2017 top-line growth of 19%. Eloctate...
...2012) Malec, L., et al. “Immune tolerance induction using Rfviifc (Eloctate).” Blood (2015) Erin McCallister, Senior Editor Alprolix Eloctate Biogen...
BioCentury | Feb 3, 2017
Company News

Biogen, Bioverativ deal

...Biogen spun out its hematology business into Bioverativ. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa for hemophilia...
...expects to begin a clinical study next half of the most advanced program, BIVV 001 (rFVIIIFc-VWF-XTEN...
...Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Bioverativ Inc. (NASDAQ:BIVV), Cambridge, Mass. Business: Hematology Meghan Sullivan Alprolix BIVV 001 efmoroctocog alfa eftrenonacog alfa Eloctate Biogen...
BioCentury | Feb 2, 2017
Company News

Biogen hematology spinout Bioverativ launches

...business into Bioverativ Inc. (NASDAQ:BIVV) as a standalone public company. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa...
Items per page:
1 - 10 of 87